Regeneron Pharmaceuticals Inc

AI Summary

Regeneron discovers and commercializes medicines for eye diseases (EYLEA for macular degeneration), allergic conditions (Dupixent for eczema and asthma), cancer (Libtayo), and rare diseases [Yahoo Finance]. The company operates through a combination of selling FDA-approved drugs and investing heavily in research partnerships to develop next-generation treatments using technologies like gene-editing and radiopharmaceuticals [Yahoo Finance].

Regeneron Pharmaceuticals is a major biotechnology company that develops treatments for eye diseases, cancer, and rare conditions, generating $14.3B in annual revenue [Yahoo Finance]. The company recently suffered a significant setback when its experimental melanoma drug combination failed in late-stage testing, causing the stock to drop sharply [Yahoo Finance]. Despite this disappointment, Regeneron maintains a strong financial position with $4.1B in free cash flow and continues expanding through partnerships in gene-editing and oncology research [Yahoo Finance].

Regeneron is financially robust with exceptional profitability and zero net debt.

Recent News

• Why Regeneron (REGN) Shares Are Trading Lower Today

  Yahoo Finance· 2026-05-20

• Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal

  Yahoo Finance· 2026-05-19

• Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

  Yahoo Finance· 2026-05-19

• Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B

  Yahoo Finance· 2026-05-19

• A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback

  Simply Wall St· 2026-05-19

• Regeneron's Late-Stage Melanoma Study Misses Primary Goal

  Yahoo Finance· 2026-05-18